370 related articles for article (PubMed ID: 27056896)
1. Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
Hille S; Dierck F; Kühl C; Sosna J; Adam-Klages S; Adam D; Lüllmann-Rauch R; Frey N; Kuhn C
Cardiovasc Res; 2016 Jun; 110(3):381-94. PubMed ID: 27056896
[TBL] [Abstract][Full Text] [Related]
2. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
3. The alteration of protein prenylation induces cardiomyocyte hypertrophy through Rheb-mTORC1 signalling and leads to chronic heart failure.
Xu N; Guan S; Chen Z; Yu Y; Xie J; Pan FY; Zhao NW; Liu L; Yang ZZ; Gao X; Xu B; Li CJ
J Pathol; 2015 Apr; 235(5):672-85. PubMed ID: 25385233
[TBL] [Abstract][Full Text] [Related]
4. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy.
Kuhn C; Frank D; Will R; Jaschinski C; Frauen R; Katus HA; Frey N
J Biol Chem; 2009 Jun; 284(25):17320-17327. PubMed ID: 19372220
[TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of pRb by cyclin D kinase is necessary for development of cardiac hypertrophy.
Hinrichsen R; Hansen AH; Haunsø S; Busk PK
Cell Prolif; 2008 Oct; 41(5):813-29. PubMed ID: 18700867
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the dual-specificity tyrosine phosphorylation-regulated kinase 1A-alternative splicing factor-calcium/calmodulin-dependent protein kinase IIδ signaling pathway in myocardial infarction-induced heart failure of rats.
He J; Yao J; Sheng H; Zhu J
J Card Fail; 2015 Sep; 21(9):751-60. PubMed ID: 26067684
[TBL] [Abstract][Full Text] [Related]
7. DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3.
Thompson BJ; Bhansali R; Diebold L; Cook DE; Stolzenburg L; Casagrande AS; Besson T; Leblond B; Désiré L; Malinge S; Crispino JD
J Exp Med; 2015 Jun; 212(6):953-70. PubMed ID: 26008897
[TBL] [Abstract][Full Text] [Related]
8. MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart.
Streicher JM; Ren S; Herschman H; Wang Y
Circ Res; 2010 Apr; 106(8):1434-43. PubMed ID: 20339119
[TBL] [Abstract][Full Text] [Related]
9. Reversible regulation of the retinoblastoma protein/E2F-1 pathway during "reverse cardiac remodelling" after ventricular unloading.
Wohlschlaeger J; Schmitz KJ; Takeda A; Takeda N; Vahlhaus C; Stypmann J; Schmid C; Baba HA
J Heart Lung Transplant; 2010 Jan; 29(1):117-24. PubMed ID: 20123249
[TBL] [Abstract][Full Text] [Related]
10. Interplay between the E2F pathway and β-adrenergic signaling in the pathological hypertrophic response of myocardium.
Major JL; Salih M; Tuana BS
J Mol Cell Cardiol; 2015 Jul; 84():179-90. PubMed ID: 25944088
[TBL] [Abstract][Full Text] [Related]
11. Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats.
Raaf L; Noll C; Cherifi M; Benazzoug Y; Delabar JM; Janel N
Int J Cardiol; 2010 Nov; 145(2):306-307. PubMed ID: 19906449
[TBL] [Abstract][Full Text] [Related]
12. The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy.
Liu L; An X; Li Z; Song Y; Li L; Zuo S; Liu N; Yang G; Wang H; Cheng X; Zhang Y; Yang X; Wang J
Cardiovasc Res; 2016 Jul; 111(1):56-65. PubMed ID: 27084844
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload.
Matsuda T; Zhai P; Maejima Y; Hong C; Gao S; Tian B; Goto K; Takagi H; Tamamori-Adachi M; Kitajima S; Sadoshima J
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20900-5. PubMed ID: 19106302
[TBL] [Abstract][Full Text] [Related]
14. The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
Soppa U; Schumacher J; Florencio Ortiz V; Pasqualon T; Tejedor FJ; Becker W
Cell Cycle; 2014; 13(13):2084-100. PubMed ID: 24806449
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.
da Costa Martins PA; Salic K; Gladka MM; Armand AS; Leptidis S; el Azzouzi H; Hansen A; Coenen-de Roo CJ; Bierhuizen MF; van der Nagel R; van Kuik J; de Weger R; de Bruin A; Condorelli G; Arbones ML; Eschenhagen T; De Windt LJ
Nat Cell Biol; 2010 Dec; 12(12):1220-7. PubMed ID: 21102440
[TBL] [Abstract][Full Text] [Related]
16. Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction.
Mori J; Basu R; McLean BA; Das SK; Zhang L; Patel VB; Wagg CS; Kassiri Z; Lopaschuk GD; Oudit GY
Circ Heart Fail; 2012 Jul; 5(4):493-503. PubMed ID: 22705769
[TBL] [Abstract][Full Text] [Related]
17. Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy.
Huang S; Zou X; Zhu JN; Fu YH; Lin QX; Liang YY; Deng CY; Kuang SJ; Zhang MZ; Liao YL; Zheng XL; Yu XY; Shan ZX
J Cell Mol Med; 2015 Mar; 19(3):608-19. PubMed ID: 25583328
[TBL] [Abstract][Full Text] [Related]
18. FasL expression in cardiomyocytes activates the ERK1/2 pathway, leading to dilated cardiomyopathy and advanced heart failure.
Huby AC; Turdi S; James J; Towbin JA; Purevjav E
Clin Sci (Lond); 2016 Feb; 130(4):289-99. PubMed ID: 26566650
[TBL] [Abstract][Full Text] [Related]
19. Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration.
Branchi I; Bichler Z; Minghetti L; Delabar JM; Malchiodi-Albedi F; Gonzalez MC; Chettouh Z; Nicolini A; Chabert C; Smith DJ; Rubin EM; Migliore-Samour D; Alleva E
J Neuropathol Exp Neurol; 2004 May; 63(5):429-40. PubMed ID: 15198122
[TBL] [Abstract][Full Text] [Related]
20. Expression and activity of the retinoblastoma protein (pRB)-family proteins, p107 and p130, during L6 myoblast differentiation.
Kiess M; Gill RM; Hamel PA
Cell Growth Differ; 1995 Oct; 6(10):1287-98. PubMed ID: 8845306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
